2Sutton I, Winer JB. The immunopathogenesis of paraneoplastic neurological syndromes. Clinical Science, 2002,102:475-486.
3Krueger P, Nitz C,Foster R,et al. A new small cell lung cancer(SCLC)-specific marker discovered through antigenic substraction of neuroblastome cells. Cancer Immunol Immunother, 2003, 52:367-377.
4Giometto B,Taralotot B,Graus F. Autoimmunity in paraneoplastic neurological syndroms. Brain Pathol, 1999,9:261-273.
2Albert M L,Austin L M,Darnell R B.Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration[J].Ann Neurol,2000,47(1):9-17.
4Miyake Y,Kodama T,Yamaguchi K.Pro-gastrin releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma.Cancer Res,1994,54:2136-2140.
5Aoyagi K,Yamaguchi K,Urakami K,et al.Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement.J Cancer Res,1995,86:698-705.
6Okusaka T,Eguchi K,Kasai T,et al.Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer.Clin Cancer Res,1997,3:123-127.
7Benjamin N,Haim B,Nili R,et al.The diagnostic and prognostic value of ProGRP in lung cancer.Anticancer Res,2009,29:4827-4832.
8Ono A,Naito T,Ito I,et al.Correlations between serial progastrin-releasing peptide and neuron-specific enolase levels,and the radiological response to treatment and survival of patients with small-cell lung cancer.Lung Cancer,2012,76:439-444.
9Hirose T,Okuda K,Yamaoka T,et al.Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer? Lung Cancer,2011,71:224-228.
